Stuttering Therapeutics Market Set for 14% CAGR Surge by 2033

According to a recent industry study analysis by Future Market Insights, the global Stuttering Therapeutics Market is expected to expand at a compound annual growth rate (CAGR) of 14% between 2023 and 2033. The industry is being driven by several factors, including increased support and awareness for the illness, technological advancements, and the growing prevalence of stuttering.

Stuttering is a speech disorder that affects millions of people worldwide. The disorder is characterized by interruptions in the flow of speech, including repeated sounds, syllables, or words. Stuttering can significantly impact an individual’s quality of life, including their social interactions, academic and career success, and overall emotional well-being.

Unleash the extraordinary. Claim your sample for unmatched efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16822

The increasing prevalence of stuttering is a key driver of the stuttering therapeutics market. According to the Stuttering Foundation, approximately 1% of the world’s population has a stuttering disorder. This high incidence of stuttering creates significant opportunities for stuttering therapeutics manufacturers, as more individuals seek diagnosis and treatment for the disorder.

Advancements in technology are also driving the growth of the stuttering therapeutics market. Electronic fluency devices, smartphone apps, and other technologies are being developed to help manage the symptoms of stuttering. These technologies offer non-invasive, convenient, and cost-effective options for individuals with stuttering, and are gaining popularity in the market.

Moreover, increased awareness and advocacy for stuttering are also driving the growth of the stuttering therapeutics market. There has been a significant increase in awareness and advocacy for stuttering in recent years, which has helped reduce the stigma surrounding the disorder and increased access to diagnosis and treatment for individuals with the disorder.

Key Takeaways:

From 2018 to 2022, the Stuttering Therapeutics market grew at a CAGR of 11%.
The global Stuttering Therapeutics market is expected to grow with a 14% CAGR during 2023 to 2033.
As of 2033, the Stuttering Therapeutics Market is expected to reach US$ 159.41 Million.
According to the FMI analysis, the hospitals segment accounts for the largest market share.
North America is expected to possess 40% market share for the Stuttering Therapeutics market.
The East South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Stuttering Therapeutics.” says an FMI analyst

Market Competition

Key players in the market include companies such as Competition Deep Dive, Auspex Pharmaceuticals, Inc., GlaxoSmithKline plc., Johnson Johnson Services, Merck Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, AstraZeneca, AbbVie Inc. along with healthcare providers and technology companies among other global players.

In October 2022, Vivera announced that the US Patent and Trademark Office (USPTO) has granted a US patent allowance for the Company’s method and device for evaluating and providing feedback on Speech Fluency. Stuttering, a speech disorder that causes disfluencies in speech, affects 70 million individuals across the globe. Although there are treatments available, it can be challenging for clinicians to assess stuttering accurately, as its severity may fluctuate over time and in different situations.

Recognizing the need for a more precise evaluation of patient speech disfluencies in real-world settings, Vivera developed a stuttering severity assessment device. This innovative device allows for continuous monitoring of a patient’s stuttering, enabling a more accurate assessment and providing feedback to the patient in real-time. By gathering personalized patient data, clinicians can monitor the therapeutic effects of treatment and adjust therapy accordingly.

Key Segments:

Treatment: